The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays. (24th March 2018)

• Record Type: Journal Article
• Authors: Jacquemin, M.; Toelen, J.; Feyen, L.; Schoeters, J.; Van Horenbeeck, I.; Vanlinthout, I.; Debasse, M.; Vanassche, T.; Peerlinck, K.; Verhamme, P.
• Is Part Of: International journal of laboratory hematology. Volume 40:Number 4(2018:Aug.)
• Page Start: 442
• Page End: 447
• Publication Date: 2018-03-24
• Subjects: anticoagulants -- antiphospholipid syndrome -- dabigatran -- factor VIII -- idarucizumab -- protein C; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; 616.15005
• DOI: 10.1111/ijlh.12807
• Languages: English
• ISSNs: 1751-5521

Abstract

Abstract: Introduction: The direct thrombin inhibitor dabigatran interferes with thrombophilia screening and with the diagnosis of hemostasis disorders that develop during treatment with the anticoagulant. In vitro addition of idarucizumab, a humanized antibody fragment that binds dabigatran, to plasma samples containing dabigatran fully neutralizes the drug. This study was carried out to determine whether binding of dabigatran on selected insoluble commercial adsorbent material, DOAC‐STOP R, was as efficient as idarucizumab to neutralize the anticoagulant activity of the drug in vitro. Methods: Coagulation assays sensitive to dabigatran were carried out with patient and control plasma samples spiked with dabigatran and supplemented with idarucizumab or incubated with adsorbent material. Results: In samples containing upto 10 000 ng/mL dabigatran, the adsorption procedure was at least as efficient as the addition of idarucizumab to neutralize the activity of the anticoagulant drug. Neither the adsorption procedure nor the addition of idarucizumab did impair routine coagulation assays carried out with plasma devoid of dabigatran, such as the activated partial thromboplastin time, prothrombin time, fibrinogen Clauss, and the thrombophilia screening assays used to detect antiphospholipid antibodies or activated protein C resistance. In addition, the adsorption procedure did not interfere with the detection of lupus anticoagulant samples. Conclusions: Adsorption of dabigatran in plasma samples containing the drug neutralizes its activity as efficiently as the addition of idarucizumab. This method allows the evaluation of thrombophilia markers without interruption of anticoagulation therapy or the detection of hemostasis disorders in patients treated with the drug.